Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

NCT01444417 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Thrombocytopenic Purpura
Thrombocytopenia
Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Thrombocytopenic Purpura
Immune Thrombocytopenia

Interventions

DRUG: Romiplostim
DRUG: Placebo

Sponsor

Amgen